A warm welcome to two new arrivals who joined the Alzheimer Europe team in April: Isabelle Collot, who is our new Conference Coordinator and Margarita Reyes, who joins the team as a Communications Officer. We are all delighted to be working with them both!
The European Commission has granted EU authorisation for lecanemab to treat mild cognitive impairment (MCI) in the early stages of Alzheimer’s disease. This authorisation comes under strict conditions, with the drug being for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain.
Alzheimer Europe, Alzheimer Uniti Italia and Federazione Alzheimer Italia would like to thank everyone who submitted abstracts for the 35th Alzheimer Europe Conference (#35AEC), taking place from 6-8 October 2025, in Bologna (Italy). A record number of 926 abstracts was received this year, which will be reviewed by our Scientific Committee during May.
Alzheimer Europe's 
A warm welcome to two new arrivals who joined the Alzheimer Europe team in April: Isabelle Collot, who is our new Conference Coordinator and Margarita Reyes, who joins the team as a Communications Officer. We are all delighted to be working with them both!
The European Commission has granted EU authorisation for lecanemab to treat mild cognitive impairment (MCI) in the early stages of Alzheimer’s disease. This authorisation comes under strict conditions, with the drug being for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain. 
Alzheimer Europe, Alzheimer Uniti Italia and Federazione Alzheimer Italia would like to thank everyone who submitted abstracts for the 35th Alzheimer Europe Conference (#35AEC), taking place from 6-8 October 2025, in Bologna (Italy). A record number of 926 abstracts was received this year, which will be reviewed by our Scientific Committee during May.